Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. The aetiology of anti-CTLA4-induced hypophysitis remains unresolved. Next, the severity of the skin AE needs to be evaluated by a careful and thorough physical examination of the skin including the mucosal areas, an appreciation of the general patient status (fever, enlarged lymph nodes etc. Patients may present with different complaints. In the case of mild neurological AEs, withhold ICPi and perform work-up (MRI scan, lumbar puncture) to define nature of neurotoxicity. FC has reported being a board member of Merck Sharpe & Dohme and Bristol-Myers Squibb and honoraria from Bristol-Myers Squibb; CR has reported consultancy for Roche, Bristol-Myers Squibb, Amgen, Merck Sharpe & Dohme, Novartis and Merck; KK has reported lecture honoraria and/or consultancy from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck KGaA, Merck Sharpe & Dohme, Novartis, Pfizer, Roche and Roche Diagnostics; JL has reported honoraria and research grants from Bristol-Myers Squibb, Merck Sharpe & Dohme, Novartis, Pfizer, Eisai, GlaxoSmithKline, Kymab, Roche/Genentech, Secarna, Fabre and EUSA Pharma; JH, SP and KJ has reported honoraria from Amgen, Merck, MSD, Helsinn, Tesaro and Hexaland and being a member of the advisory board of Merck, MSD, Helsinn and Tesaro. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. eCollection 2018. Acute interstitial pneumonitis/diffuse alveolar damage syndrome (DADS) is the most acute, life threatening event [. Opdivo: Highlights of prescribing information, 2014, pp. *Pituitary Axis bloods: 9 am cortisol (or random if unwell and treatment cannot be delayed), ACTH, TSH/FT4, LH, FSH, oestradiol if premenopausal, testosterone in men, IGF-1, prolactin. All patients undergoing ICPi therapy should be assessed for signs and symptoms of hepatitis with serum transaminases and bilirubin measured before every cycle of treatment. intravenous; LCI, lung clearance index; LFT, liver function test; LKM, liver kidney microsomal; MMF, mycophenolate mofetil; PCR, polymerase chain reaction; SLA/LP, soluble liver antigen/liver-pancreas antibody; SMA, smooth muscle autoantibody; ULN, upper limit of normal; US, ultrasound. There was a confirmed PSA response in 27.6% of patients, an unconfirmed PSA response in 11.4% of patients, and a CTC0 response in 23.1% of patients. Ipilimumab following radiotherapy (CA184-043 phase III trial): median OS of ipilimumab of 11.0 months vs median OS of placebo of 10.0 months (piecewise HR 0-5 months of 1.49, 95% CI 1.12-1.99; piecewise HR 5-12 months of 0.66, 95% CI 0.51-0.86; piecewise HR >12 months of 0.66, 95% CI 0.52-0.84).